ArticleAnnals of neurosciences2015
Safety of human embryonic stem cells in patients with terminal/incurable conditions- a retrospective analysis.
Article in Annals of neurosciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Induced pluripotent stem cell technology for spinal cord injury: a promising alternative therapy.Neural regeneration research · 2021Article
- Ethical Guiding Principles of "Do No Harm" and the "Intention to Save Lives" in relation to Human Embryonic Stem Cell Research: Finding Common Ground between Religious Views and Principles of Medical Ethics.Asian bioethics review · 2019Article
- Gene Expression Patterns of Royan Human Embryonic Stem Cells Correlate with Their Propensity and Culture Systems.Cell journal · 2019Article
- Improvement of common variable immunodeficiency using embryonic stem cell therapy in a patient with lyme disease: a clinical case report.Clinical case reports · 2018Article
- Single-photon emission tomography imaging in patients with Lyme disease treated with human embryonic stem cells.The neuroradiology journal · 2018Article
- Advances in Regenerative Medicine and Tissue Engineering: Innovation and Transformation of Medicine.Stem cells international · 2018Review
- A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells.Stem cells and cloning : advances and applications · 2018Review
- Nutech functional score: A novel scoring system to assess spinal cord injury patients.World journal of methodology · 2017Article
- Comparison of Nutech Functional Score with European Stroke Scale for Patients with Cerebrovascular Accident Treated with Human Embryonic Stem Cells: NFS for CVA Patients Treated with hESCs.Journal of vascular and interventional neurology · 2017Article
- Magnetic resonance imaging tractography as a diagnostic tool in patients with spinal cord injury treated with human embryonic stem cells.The neuroradiology journal · 2017Article
- A review of the emerging potential therapy for neurological disorders: human embryonic stem cell therapy.American journal of stem cells · 2017Review
- Evaluation of patients with multiple sclerosis using reverse nutech functional score and expanded disability status scale after human embryonic stem cell therapy.Clinical and translational medicine · 2016Article
- Human Embryonic Stem Cell Therapy in Chronic Spinal Cord Injury: A Retrospective Study.Clinical and translational science · 2016Article
- Human embryonic stem cells (hESCs) in the treatment of emphysematous COPD: a case report.Clinical case reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman embryonic stem cells (hESCs) are pluripotent cells that have the potential to self-renew and differentiate into all types of human cells. PURPOSE: The present study was aimed at establishing the safety of hESC therapy in patients with terminal/incurable conditions.
methodsThis was a single cohort study conducted at Nutech Mediworld, New Delhi. The patients suffering from various degenerative diseases were included in the study from year 2002 to 2004. hESCs (0.25 mL) were injected under skin in the abdominal wall. The safety of hESC therapy was evaluated by assessing the AEs experienced by patients during the study. Any disabling symptom/ sign, teratoma or antigen-antibody reaction that a patient suffered post transplantation of hESCs was considered as an AE.
resultsA total of four, six and twenty three patients received hESC therapy in the year 2002, 2003 and 2004 respectively. Pain and fever were the most common AEs observed during the study. Other AEs included headache, mild pain in the abdomen, swelling of legs (edema), urinary tract infection (UTI), rash/erythema, pain at the lower back and limbs and body ache. All the AEs reported were mild in nature and resolved within one or two days with symptomatic medication and rest. No serious AEs were reported. The improvement in specific parameters of the patients was observed after the therapy.
conclusionhESCs used in the present study are safe for use in humans afflicted with incurable/terminal conditions. Future, prospective controlled studies to substantiate the present study are ongoing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.